Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2026)

Ptc Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $28.0 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 117.91% year-over-year to $28.0 million in Q1 2026; TTM through Mar 2026 was $62.2 million, a 11.99% increase from a year earlier, with the FY2025 full-year figure at $47.0 million, down 18.09% from the prior year.
• Cost of Revenue grew to $28.0 million in Q1 2026 per PTCT's latest filing, from $7.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $29.1 million in Q4 2023 and bottomed at $7.0 million in Q4 2025.
• The 5-year median for Cost of Revenue is $12.9 million (2025), against an average of $14.3 million.
• Across the five-year window, Cost of Revenue soared 167.31% in 2023 and plunged 57.32% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $10.9 million in 2022, then soared by 167.31% to $29.1 million in 2023, then tumbled by 44.08% to $16.3 million in 2024, then plunged by 57.32% to $7.0 million in 2025, then surged by 303.28% to $28.0 million in 2026.
• Per Business Quant, the three latest PTCT Cost of Revenue figures stand at $28.0 million (Q1 2026), $7.0 million (Q4 2025), and $15.8 million (Q3 2025).